Allegations of "materially false and misleading statements", surrounding a FDA New Drug Application, made to both AEZS shareholders and analysts by David A. Dodd resulted in Dodd named as defendant in class action suit.
Dodd and Theodore got the boot from AEterna Zentaris Inc. (AEZS) prior to joining Medizone Int. Inc. (MZEI)
On July 20, 2017, Aeterna terminated Mr. Dodd's employment as CEO for cause, including for his repeated refusal to implement express directives of the Board.
Mr. Theodore's employment was terminated on July 28, 2017.
Aeterna Zentaris Commences Legal Action Against David Dodd and Philip Theodore
*Aeterna alleges among other things, that former CEO Dodd and former General Counsel Theodore breached fiduciary duties owed to Company. *Company also alleges that defendants developed secret plans to acquire the U.S. rights to MacrilenTM and mount a proxy contest for control of the Board with assistance from shareholder Graeme Roustan. *Aeterna also alleges that Dodd and Theodore conveyed and used Aeterna’s confidential information without authorization.
News 
Market Data 
Discover 
AI
